Search

Displaying results 51 - 60 of 108 in total
  1. Indication

    Persistent Cervical Cancer

    go.drugbank.com/conditions/DBCOND0125497
    Drugs: Bevacizumab · Pembrolizumab
  2. Indication

    Stage III Melanoma

    go.drugbank.com/conditions/DBCOND0028661
    Drugs: Pembrolizumab · Trametinib
  3. Indication

    Metastatic HER2 negative Gastric Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0162412
    Drugs: Pembrolizumab · Tislelizumab
  4. Indication

    Metastatic HER2 negative Gastroesophageal Junction Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0171123
    Drugs: Pembrolizumab · Tislelizumab
  5. Indication

    Metastatic Mismatch Repair Deficient Colorectal Cancer

    go.drugbank.com/conditions/DBCOND0144310
    Drugs: Nivolumab · Pembrolizumab
  6. Indication

    Unresectable Microsatellite Instability High Colorectal Cancer

    go.drugbank.com/conditions/DBCOND0144306
    Drugs: Nivolumab · Pembrolizumab
  7. Indication

    Advanced Endometrial Cancer

    go.drugbank.com/conditions/DBCOND0050728
    Drugs: Carboplatin · Doxorubicin · Pembrolizumab
  8. Indication

    Lung Cancer, Nonsmall Cell, Stage IIIA

    go.drugbank.com/conditions/DBCOND0150709
    Drugs: Atezolizumab · Gemcitabine · Pembrolizumab
  9. Indication

    Metastatic cutaneous squamous cell carcinoma

    go.drugbank.com/conditions/DBCOND0017288
    Drugs: Cemiplimab · Cosibelimab · Pembrolizumab
  10. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-di...